Cargando…
Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives
Duchenne muscular dystrophy (DMD) is a disease linked to the X-chromosome which affects 1 in 3,600-6,000 newborn males. It is manifested by the absence of the dystrophin protein in muscle fibres, which causes progressive damage leading to death in the third decade of life. The only medication so far...
Autores principales: | DE LOS ANGELES BEYTÍA, MARIA, VRY, JULIA, KIRSCHNER, JANBERND |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore SpA
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440798/ https://www.ncbi.nlm.nih.gov/pubmed/22655510 |
Ejemplares similares
-
Adult care for Duchenne muscular dystrophy in the UK
por: Rodger, Sunil, et al.
Publicado: (2014) -
European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences
por: Vry, Julia, et al.
Publicado: (2016) -
Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Landfeldt, Erik, et al.
Publicado: (2020) -
Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey
por: Schorling, David C., et al.
Publicado: (2020) -
Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)